C3G
Clinical trials for C3G explained in plain language.
Never miss a new study
Get alerted when new C3G trials appear
Sign up with your email to follow new studies for C3G, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare kidney disease in phase 3 trial
Disease control Recruiting nowThis study tests a new drug, iptacopan, for people with a rare kidney disease called C3G. The goal is to see if iptacopan can reduce protein in the urine and protect kidney function better than a placebo. About 98 participants aged 12 to 60 will take either the drug or a placebo …
Matched conditions: C3G
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug ADX-038 aims to control rare kidney diseases
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…
Matched conditions: C3G
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:44 UTC